相关实验视频
Updated: May 28, 2025

07:56
Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells
Published on: July 22, 2019
11.1K
利用基于载体的基因干扰来提高CAR T细胞的有效性
Beatriz C Oliveira1, Saaurav Bari1, J Joseph Melenhorst1
1Cell Therapy & Immuno-Engineering Program, Center for Immunotherapy and Precision Immuno-Oncology, Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44016, USA.
Cancers
|February 13, 2025
概括
化学抗原受体 (CAR) T细胞疗法在治疗慢性淋巴细胞白血病 (CLL) 等B细胞癌方面显示出有前途. 载体整合部位和基因中断,如TET2突变,显著影响CAR T细胞功效和患者的结果.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 抗CD19CAR T细胞疗法为复发性/耐药性B细胞恶性瘤,包括CLL提供治疗潜力.
- 治疗的成功是有限的,只有不到30%的CLL患者获得长期反应.
- 卡尔T细胞疗法的有效性取决于具有扩张和持久能力的T细胞子集.
研究的目的:
- 对CAR T细胞治疗中载体集成的现有知识进行审查.
- 分析矢量集成和基因组中断对临床结果的影响.
- 为开发更有效的CAR T细胞疗法提供信息.
主要方法:
- 文献综述综合了CAR T细胞治疗中载体集成和临床结果的数据.
- 对案例研究和独立研究的分析,将基因组改变与CAR T细胞功能联系起来.
- 探索先前存在的突变 (例如,TET2) 和载体诱导的基因破坏的作用.
主要成果:
- 一个先前存在的TET2突变,加上CAR载体诱导的干扰,在一个CLL患者中增强了CAR T细胞克隆功效.
- CAR载体的基因组插入部位影响瘤向能力.
- 矢量诱导的基因干扰可能会影响CAR T细胞功能和临床疗效.
结论:
- 了解矢量集成及其对T细胞功能的影响对于改善CART细胞治疗至关重要.
- 准基因组因素可能会增强CAR T细胞的效能和持久性.
- 对矢量设计和患者遗传学的进一步研究可以优化B细胞恶性瘤的治疗结果.
相关概念视频
In-vitro Mutagenesis
13.7K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
13.7K
Tumor Immunotherapy
464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464
Gene Therapy
25.1K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.1K

